Investigators conducted a retrospective study to better understand whether there is an equally shared risk for C difficile infection across immunosuppressant classes.
A multidisciplinary panel comprising members from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America created guidelines for health care professionals caring for patients with C difficile infection.
This is the first prospective investigation comparing the efficacy and tolerability of 2 treatments for nitroimidazole-refractory giardiasis in international travelers.
The association was observed with colon cancer but not rectal cancer.
Nearly one in five patients hospitalized with COVID-19 has gastrointestinal (GI) symptoms, with persistence of symptoms in some patients for up to six months.
Researchers analyzed the presence and effect of mucosal biofilms in patients with irritable bowel syndrome and ulcerative colitis.
Because outcomes of appendectomy vary by patient age, family income, and transfer status, the researchers compared outcomes in these subgroups.
Investigators evaluated the safety and effectiveness of bezlotoxumab to prevent recurrent C difficile infection in patients having undergone solid organ or hematopoietic cell transplantation.
Investigators assessed the immune response to Clostridioides difficile in immunocompromised patients.
Investigators assessed whether choice of antibiotic has an impact on shedding of Clostridioides difficile spores in hospitalized patients.
